Sentences with phrase «survival than patients»

These findings for scoring expression were agreed with Gillet et al., 1996 [24], who stated in their study that, moderate / strong staining of Cyclin D1 had a longer relapse - free survival than patients whose tumors stained weakly or negatively for Cyclin D1 with a great significant difference (P = 0.007).

The MSLT - 1 trial demonstrated that patients with a positive SLN undergoing CLND had far better melanoma - specific survival than those patients who manifested nodal recurrence either on the observation arm or after a false - negative SLN biopsy (10 - year melanoma - specific survival rates: 62.1 % vs 41.5 % and 34.4 %, respectively).

Not exact matches

In a later study of the well - being of coronary patients, Holden (1981) reported that ownership of a pet among ninety - three patients was the strongest predictor of survival, stronger even than human relationships.

Researchers from Aston Medical School in Birmingham looked at more than 900,000 patients with high blood pressure, high cholesterol and type 2 diabetes and found marriage led to higher survival rates.

Sara Hiom, Cancer Research UK's director of health information, said: «Survival rates for breast cancer have been improving for more than 20 years - eight out of ten patients now survive more than five years.

A team of Swedish researchers finds that early cardiopulmonary resuscitation more than doubles the chance of survival for patients suffering out - of - hospital cardiac arrest.

This recommendation is based on a separate study published in The Lancet, for which Garon was the senior author, showing longer survival than chemotherapy among patients with any positive staining for PD - L1.

The mean survival time for this disease, which predominantly occurs in the elderly, is less than a year for patients over 65 years.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

«Moreover, our initial data suggest that subtypes of AML with a poor prognosis are likely to be sensitive to this new therapeutic approach,» she says, adding that less than 10 percent of patients with certain forms of AML achieve long - term survival.

Interestingly, female patients had 76 percent higher odds for survival than men.

The malignancy often remains undiagnosed until the cancer has spread, leaving patients with a bleak prognosis and a five - year survival rate of less than 30 percent.

«This greater than expected survival in older patients selected for operative therapy is noteworthy,» said Dr. Fernandez, «especially considering that the prevalence of lung cancer is expected to increase as the population continues to grow older and more people survive into old age.»

«African - American multiple myeloma patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy - to - treat cancer.

With a three - year survival rate of 94.39 percent for all adult kidney recipients — above the 92.62 percent national average — UCSF has more patients on the kidney transplant waiting list than any other U.S. transplant center.

The median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years.

Although treatment has improved, the surgery rate in patients with ductal adenocarcinoma is around 30 percent and the five - year survival rate is less than 20 percent.

Studies show that PD - 1 inhibitors are effective for a larger proportion of melanoma patients than ipilimumab alone — and, in combination with that drug, they achieve a two - year survival rate of 80 percent.

The five year disease - free and overall survival rates for patients with high - risk malignant germ cell tumours remains less than 50 %, and so accurate diagnosis and monitoring is crucial to improving outcomes for patients.

Median progression - free survival among patients receiving selumetinib was more than double that of patients receiving chemotherapy (15.9 weeks vs. 7 weeks).

Because of the high survival rates of childhood cancer — close to 80 percent — more cancer patients than ever are reaching adulthood and many face fertility problems.

Reports of laboratory advances have to be hedged in cautious language for the sake of patients and their families, talking in terms of «treatment» and «survival» rather than «cures».

Study results show that patients with prior knowledge of MGUS had better overall survival (median 2.8 years) than patients with MM who didn't know when they had MGUS (median survival 2.1 years), although patients with prior knowledge of their MGUS status had more coexisting illnesses.

«The significant improvement in overall survival with pembrolizumab was remarkable given that more than 40 % of patients crossed over from the control arm to pembrolizumab after progression of the disease,» said Reck.

The researchers note «strong indications» that patients» survival after THA is improving, and that patients undergoing THA tend to live longer than a matched general population.

Patients who had sentinel node biopsies had significantly greater 10 - year disease - free survival rates than patients who underwent nodal obsePatients who had sentinel node biopsies had significantly greater 10 - year disease - free survival rates than patients who underwent nodal obsepatients who underwent nodal observation.

Ceritinib provides longer progression - free survival than chemotherapy in crizotinib - pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND - 5 study presented at the ESMO 2016 Congress in Copenhagen.

Patients who had surgery in sunny months — May to August — had a roughly 30 percent higher overall survival rate or time to cancer recurrence than did those getting surgery in the winter.

Data revealed today at The International Liver Congress ™ 2015 show that the long - term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5 - year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95 % of patients surviving at 5 years and a significant proportion of deaths coming from liver - unrelated causes.

Hospitalized heart failure patients in all age groups within the study and with all levels of ejection fraction had significantly lower rates of survival after five years and a higher risk of re-hospitalization than people in the United States without heart failure.

In the total patient population, the 5 - year overall survival rate was 95 %, although it was significantly higher in non-cirrhotic (97 %) than cirrhotic patients (92 %).

«Predicting survival is far less certain for a threatened species than for a human patient,» wrote leaders from 10 conservation organizations in a 2009 critique (pdf).

Usually, treatment would require whole - brain radiation which is extremely toxic and the average survival time is just 3 - 6 months from diagnosis, with fewer than 20 per cent of patients surviving more than one year.

Similarly, 29 patients had low TS levels and significantly longer average survival times (36 months) than patients with high TS levels (15 months).

The survival of patients with stage T4a larynx cancer who are untreated is typically less than one year.

Breast cancer patients with a mutation in both copies of the NQO1 gene have a 20 % lower survival rate 5 years after treatment than do patients without the mutation, according to a new study of more than 2000 Finnish women.

Among patients whose tumours carried EGFR mutations, and who were treated with targeted therapies, those whose tumours were also PD - L1 positive took longer to progress, and tended toward longer overall survival than PD - L1 negative patients.

Methylnaltrexone relieved constipation for more than half of the patients, but brought no additional survival, even for those who responded to the drug's digestive effects.

A national trial involving more than 8,000 patients has revealed that giving oxygen to stroke victims makes no difference to their recovery or chances of survival.

Most importantly, patients who were negative for PD - L1 expression survived around 11 months longer than patients who were positive for PD - L1 expression (median survival 4.79 vs 16.3 months).

He points to a study of breast cancer patients that provides evidence that survival has to do more with how people deal with emotions than how they feel.

New treatments are urgently needed for these patients, less than half of whom currently enjoy long - term, disease - free survival.

Some patients given both treatments lived significantly longer (years) than expected, while the overall median survival increased by 59 % (2.6 months).

Patients who were taking antacids had significantly better overall survival than those who did not take them.

Kidney dysfunction is a frequent complication affecting more than 50 percent of all cancer patients, and is directly linked to poor survival.

Results showed an increased survival of 13.6 months for patients treated with ADT plus docetaxel than with ADT alone.

Despite improvements in OS and CSS, survival rates following RT remained lower than those for elderly patients who received surgery.

However, in resource - rich environments in Europe and the USA, EVD kills less than 20 % of patients infected, suggesting that a better allocation of resources could help boost the survival rate in Africa.

Patients younger than 65 years, had average progression - free survival times of 11.7 months (combination), 5.5 months (nivolumab) and 2.8 months (ipilimumab), while the 262 patients aged between 65 and 75 had average progression - free survival times of 11.1 months, 12.7 months and 2.9 months respePatients younger than 65 years, had average progression - free survival times of 11.7 months (combination), 5.5 months (nivolumab) and 2.8 months (ipilimumab), while the 262 patients aged between 65 and 75 had average progression - free survival times of 11.1 months, 12.7 months and 2.9 months respepatients aged between 65 and 75 had average progression - free survival times of 11.1 months, 12.7 months and 2.9 months respectively.

We've performed more than 600 lifesaving lung transplants, and our patients» one - year survival rate is No. 1 in the region, exceeding the national average.